This seems interesting - less frequent is probably a good thing for many people (to make it easier to remember to take).
Alkermes recently announced the submission of a supplemental New Drug Application to the FDA for a 2-month dosing interval of Aristada extended-release injectable suspension for schizophrenia.
Read the full story here: